Altimmune to Participate at the H.C. Wainwright Global Life Sciences Conference

GAITHERSBURG, Md., March 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at H.C. Wainwright Global Life Sciences Conference, being held April 8-10 in Monte Carlo, Monaco.

About AltimmuneAltimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.

Contacts:Bill EnrightPresident and CEOPhone: 240-654-1450[email protected]

Ashley RobinsonLifeSci Advisors, LLC617-535-7742[email protected]

You May Also Be Interested In

• Altimmune, Inc. (ALT) Tops Q2 EPS by 3c
• Reconnect, a Contender for Best Resort in Sulawesi, Plans 2027 Expansion
• Miami Homes Now Sit 125 Days on the Market: Cash Out Your Home Is Responding to Growing Homeowner Demand for Fast, Flexible Cash Sales